Quercetin Blocks Ebola Virus Infection by Counteracting the VP24 Interferon-Inhibitory Function
Open Access
- 23 June 2020
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 64 (7)
Abstract
Ebola Virus (EBOV) is among the most devastating pathogens causing fatal hemorrhagic fever in humans. The 2013–2016 epidemics resulted in over 11000 deaths, while another outbreak is currently ongoing. Since there is no FDA-approved drug so far to fight EBOV infection, there is an urgent need to focus on drug discovery. Considering the tight correlation between the high EBOV virulence and its ability to suppress the type-I Interferon (IFN-I) system, identifying molecules targeting viral protein VP24, one of the main virulence determinants blocking IFN response, is a promising novel anti-EBOV therapy approach. Hence, in the effort of finding novel EBOV inhibitors, a screening of a small set of flavonoids was performed, showing that Quercetin and Wogonin can suppress the VP24 effect on IFN-I signaling inhibition. The mechanism of action of the most active compound, Quercetin, showing an IC50 value of 7.4 μM, was characterized to significantly restore the IFN-I signaling cascade, blocked by VP24, by directly interfering with the VP24 binding to karyopherin-α and thus restoring P-STAT1 nuclear transport and IFN genes transcription. Quercetin significantly blocked viral infection, specifically targeting EBOV VP24 anti-IFN-I function. Overall, Quercetin is the first identified inhibitor of the EBOV VP24 anti-IFN function, representing a molecule interacting with a viral binding site that is very promising for further drug development aiming to block EBOV infection at the early steps.Keywords
This publication has 64 references indexed in Scilit:
- A Randomized, Controlled Trial of Ebola Virus Disease TherapeuticsNew England Journal of Medicine, 2019
- Antiviral Agents Against Ebola Virus Infection: Repositioning Old Drugs and Finding Novel Small Molecules2018
- Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trialThe Lancet, 2015
- Ebola Virus VP24 Targets a Unique NLS Binding Site on Karyopherin Alpha 5 to Selectively Compete with Nuclear Import of Phosphorylated STAT1Cell Host & Microbe, 2014
- Mutations Abrogating VP35 Interaction with Double-Stranded RNA Render Ebola Virus Avirulent in Guinea PigsJournal of Virology, 2010
- Ebolavirus VP24 Binding to Karyopherins Is Required for Inhibition of Interferon SignalingJournal of Virology, 2010
- Ebola Virus VP24 Proteins Inhibit the Interaction of NPI-1 Subfamily Karyopherin α Proteins with Activated STAT1Journal of Virology, 2007
- Molecular Determinants of Ebola Virus Virulence in MicePLOS Pathogens, 2006
- Ebola Virus VP24 Binds Karyopherin α1 and Blocks STAT1 Nuclear AccumulationJournal of Virology, 2006
- Molecular Characterization of Guinea Pig-Adapted Variants of Ebola VirusVirology, 2000